Valuation of APRI and Forns models for non-invasive diagnosis of fibrosis in patients with hepatitis C in coinfected and non-coinfected with HIV;Valoración de los modelos APRI y Forns para el diagnóstico no invasivo de fibrosis en pacientes con hepatitis C coinfectados y no coinfectados por VIH

Anales de Medicina Interna

Volumn 24, Issue 8, 2007, Pages 369-374

  Ramos Paesa, Carlos ^a,b   Marcilla, F ^a   Lopez G ^a   Hueso, E ^a   Pascual, A ^a   Aguirre, J M ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b NONE   (Spain)

Author keywords

Fibrosis; Hepatitis C; Non invasive methods

Indexed keywords

IMMUNOGLOBULIN; BIOLOGICAL MARKER;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PROTHROMBIN TIME; ADULT; BLOOD; COMPARATIVE STUDY; ENZYME ASSAY; ENZYMOLOGY; EVALUATION; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; THEORETICAL MODEL; THROMBOCYTE COUNT;

ADULT; BIOLOGICAL MARKERS; CLINICAL ENZYME TESTS; DATA INTERPRETATION, STATISTICAL; FEMALE; GAMMA-GLOBULINS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MODELS, THEORETICAL; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY;

EID: 38449122023     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Solà Lamoglia R. Historia natural y situaciones clínicas de la hepatitis C. En: Diago M, Planas R, ed. Manual de hepatitis C: Aspectos biológicos, clínicos y terapéuticos. Madrid: Médica Panamericana, 2004; 81-104.
2. Niederau C, Lange S, Keintges T, Erhardt A, et al Prognosis of chronic hepatiris C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
3. Gordon SC, Bayati N, silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998: 28: 562-7.
4. Forns X, Ampurdanes S, Sánchez-Tapias JM, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35: 265-71.
5. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
6. Martín-Carbonero L. Enfermedad hepática en pacientes coinfectados. En: Soriano V, González-Lahoz ed. Coinfección por VIH y virus de la hepatitis C. Mallorca: Permanyer SL 2003: 17-24.
7. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.
8. Bedossa P, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-224.
9. Romero Gómez M, Castellano VM, Sánchez Muñoz DJ, et al. Factores agravantes de la lesión hepática en la hepatitis C crónica. Rev And Pat Digest 2002; 25: 178-83
10. Sheuer PJ, Standich REA, Dhillon AP, et al. Scoring of chronic hepatitis. Clin Liver Dis 2002: 6: 107-112.
11. Romero Gómez M, Castellano VM, Grande L, et al. Serum leptin levels correlate with heptic steatosis in chronic hepatitis C. Am J Gastroenterol 2003;98: 1135-41.
12. Forns X, Ampudanés S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
13. Wai CT, Greeson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
14. Romero Gómez M, Ramírez Martín del Campo M, Otero MA, et al. Estudio comparativo de dos modelos que utilizan parámetros bioquímicos en el diagnóstico no invasivo de la fibrosis hepática en pacientes con hepatitis C. Med Clin 2005; 124: 761-4.
15. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38: S38-S53.
16. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Bio 2003; 29: 1705-13.
17. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 481-492.
18. Poynard T, McHutchinson J, Manns M, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective stydy. Lancet 2001; 357: 1069-75.
19. Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology 2001; 34: 438-9.
20. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40: 538-544.
21. Fried M, Shiffman M, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
22. Manns M, McHutchinson J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with inteferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
23. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.
24. National Institutes of Health. Consensus Development Conference: Management of hepatitis C. Final Statement. Gastroenterology 2002; 123: 2082-99.
25. Soriano V, Miró J, García-Samaniego J, et al. Consensus Conference on chronic viral hepatitis and HIV infection: Updated Spanish Recommendations. J Viral Hepato 2004; 11: 2-17.
26. Okechukwu O, Según O. A comparative análisis of six current histological classification schemes and scoring systems used in chronic hepatitis reporting. Rev Esp Patol 2004; 37: 269-277.
27. Sheuer PJ. Classification of chronic viral hepatitis: a need for feassessment. J Hepatol 1991;13: 372-4.
28. Alberti A, Benvegnu M. Manegement of hepatitis C. J Hepatolo 2003; 38: S104-S118.
29. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36 (Supl. 1):152-60.
30. Shiffman ML. Retretment of pataients with chronic hepatitis C. Hepatology 2002; 36: S128-S134.
31. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68.276 biopsies. J Hepatol 1986; 2: 165-73.
32. Ryder SD, Irving WL, Jones DA, et al. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patiets with hepatitis C; a prospective repeat liver biopsy study. Gut 2004; 53: 451-55.
33. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index es a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904-9.
34. Baroni GS, Pastorelli A, Manzin A, et al. Heaptic stellate cell activation and liver fibrosis are associate with necroinflammatory injury and Th 1-like response in chronic hepatitis C. Liver 1999; 19: 212-9.
35. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
36. Halfon P, Bourliere M Deydier R et al. Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the Fibropaca study. Am J Gastroenterol 2006; 101: 547-55.